Table 1.
Summary of previous studies of first line ET+ anti-HER2 treatment for MBC
| Trial | Regimen | Size | Median PFS/TTP (months) | Patinets | ||
|---|---|---|---|---|---|---|
| Control | Experiment | hazard ratio (95% CI) | ||||
| Kaufmann et al.(TAnDEM) [8] | Anastrozole+/−trastuzumab | 207 | 2.4 | 4.8 | 0.63(0.47–0.84) | First line |
| Johnston et al. (EGF30008) [10] | Letrozole+/−lapatinib | 219 | 3 | 8.2 | 0.71(0.53–0.96) | First line |
| Huober et al. (eLEcTRA) [9] | Letrozole+/−trastuzumab | 92 | 3.3 | 14.1 | 0.67(0.35–1.29) | First line |
| Johnston et al. (ALTERNATIVE) [11] | AI+/−trastuzumab +/−lapatinib | 355 | 8.3/5.7 | 11 | 0.71(0.51–0.98) | First/Second line |
| Rimawi et al. (PERTAIN) [12] | Trastuzumab+AI+/−Pertuzumab | 251 | 18.9 | 15.8 | 0.65(0.48–0.89) | First line |
| Rimawi et al. (PERTAIN) [12] without induction chemotherapy | Trastuzumab+AI+/−Pertuzumab | 110 | 21.7 | 12.4 | 0.55(0.34–0.88) | First line |
ET Endocrine therapy, MBC Metastatic breast cancer